Nuzenio

Marketbeat Halozyme Therapeutics

Marketbeat Halozyme Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 8 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Timeline

Mon, 10 Aug 2026 09:27:27 GMTGradient Investments LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Sat, 08 Aug 2026 07:55:11 GMTHalozyme Therapeutics (NASDAQ:HALO) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat
Fri, 07 Aug 2026 21:22:29 GMTHalozyme Therapeutics (NASDAQ:HALO) Given New $105.00 Price Target at TD Cowen - MarketBeat
Fri, 07 Aug 2026 15:45:58 GMTCitizens Jmp Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00 - MarketBeat
Fri, 07 Aug 2026 13:09:51 GMTHalozyme Therapeutics (NASDAQ:HALO) Upgraded to "Outperform" at Leerink Partners - MarketBeat
Thu, 06 Aug 2026 23:10:37 GMTHalozyme Therapeutics (NASDAQ:HALO) Releases FY 2026 Earnings Guidance - MarketBeat

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Marketbeat Halozyme Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.